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Priscilla Henno1,2,3, Christelle Maurey4, Françoise Le Pimpec-Barthes5,6, Philippe Devillier3,7,
Christophe Delclaux5,8 and Dominique Israël-Biet5,9*Abstract
Background: Tobacco-induced pulmonary vascular disease is partly driven by endothelial dysfunction. The
bioavailability of the potent vasodilator nitric oxide (NO) depends on competition between NO synthase-3 (NOS3)
and arginases for their common substrate (L-arginine). We tested the hypothesis whereby tobacco smoking impairs
pulmonary endothelial function via upregulation of the arginase pathway.
Methods: Endothelium-dependent vasodilation in response to acetylcholine (Ach) was compared ex vivo for
pulmonary vascular rings from 29 smokers and 10 never-smokers. The results were expressed as a percentage of
the contraction with phenylephrine. We tested the effects of L-arginine supplementation, arginase inhibition
(by N(omega)-hydroxy-nor-l-arginine, NorNOHA) and NOS3 induction (by genistein) on vasodilation. Protein levels
of NOS3 and arginases I and II in the pulmonary arteries were quantified by Western blotting.
Results: Overall, vasodilation was impaired in smokers (relative to controls; p < 0.01). Eleven of the 29 smokers (the
ED+ subgroup) displayed endothelial dysfunction (defined as the absence of a relaxant response to Ach), whereas
18 (the ED− subgroup) had normal vasodilation. The mean responses to 10−4 M Ach were −23 ± 10% and 31 ± 4% in
the ED+ and ED− subgroups, respectively (p < 0.01). Supplementation with L- arginine improved endothelial function in
the ED+ subgroup (−4 ± 10% vs. -32 ± 10% in the presence and absence of L- arginine, respectively; p = 0.006), as did
arginase inhibition (18 ± 9% vs. -1 ± 9%, respectively; p = 0.0002). Arginase I protein was overexpressed in ED+ samples,
whereas ED+ and ED− samples did not differ significantly in terms of NOS3 expression. Treatment with genistein did
not significantly improve endothelial function in ED+ samples.
Conclusion: Overexpression and elevated activity of arginase I are involved in tobacco-induced pulmonary
endothelial dysfunction.
Keywords: Endothelial dysfunction, Arginase, Tobacco smokingBackground
Tobacco smoking can induce pulmonary vascular re-
modelling – even in individuals with normal or slightly
impaired lung function [1]. This remodelling can lead to
increased pulmonary vascular resistance and then pul-
monary hypertension (PH). As a well characterized fea-
ture of end-stage chronic obstructive pulmonary disease* Correspondence: dominique.israel-biet@egp.aphp.fr
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unless otherwise stated.(COPD) [2], PH can also develop in milder forms of
COPD and is acknowledged to be a significant clinical
issue with a strong, negative impact on the prognosis
[3]. Pulmonary endothelial dysfunction is thought to be
an early pathophysiological determinant of vascular re-
modelling. The condition is present in end-stage COPD
[4] but has also been observed in milder forms of COPD
and in smokers without COPD [5]. The mechanisms of
pulmonary endothelial dysfunction have not been well
elucidated but may be based (at least in part) on (i) im-
balance between the production of vasoconstrictive and
vasodilatory factors and (ii) low bioavailability of nitricThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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creases vascular smooth muscle cell proliferation. The
production of NO by endothelial nitric oxide synthase
(NOS3) is dependent on the balance between the ex-
pression and/or activity of arginases and NOS3. In the
vasculature, NOSs and arginases compete for their com-
mon substrate L-arginine (L-arg). Elevated arginase ac-
tivity reduces the availability of L-arg for NOS3 and thus
decreases the production of NO. In addition, arginases I
and II (which are also expressed by endothelial cells)
produce urea and L-ornithine [7,8]. L-ornithine metabol-
ism produces polyamines and proline, which are involved
in pulmonary vascular remodelling [9]. Consequently, ar-
ginases and NOS may have opposing effects on vascular
tone and tissue remodelling [10]. Over the last few years,
it has become increasingly clear that arginases have a
harmful role in systemic vascular conditions in animal
models and in humans (including atherosclerosis, coron-
ary artery disease, myocardial ischemia-reperfusion, dia-
betes mellitus, heart failure, hypertension and ageing)
[11-18]. Cigarette smoke can increase arginase activity
and protein expression in systemic vessels or in the lung
[19-21]. Although arginases are also expressed in the pul-
monary vasculature, [22,23] there are no literature data on
the latter’s role in tobacco-induced pulmonary endothelial
dysfunction in humans.
Hence, we decided to test the hypothesis whereby to-
bacco smoking impairs pulmonary endothelial function
through upregulation of the arginase pathway.
Methods
We obtained explants from current smokers, ex-smokers
or never-smokers undergoing lung resection for lung can-
cer in a major university hospital (Hôpital Européen
George Pompidou, Paris, France). The study’s objectives
and procedures were approved by the local independent
ethics committee, and all patients gave their written, in-
formed consent to participation in the study.
Tissue preparation
Immediately after excision, lung tissue samples were
placed in Krebs-Henseleit solution (mM: 120 NaCl, 4.7
KCl, 2.5 CaCl2, 1.2 MgCl2, 15 NaHCO3, 1.2 KH2PO4, 11
D-glucose and 10 HEPES, pH 7.4) and immediately
transported to our laboratory. After intralobar arteries
had been carefully dissected free of parenchyma and ad-
hering connective tissue, several rings (3 to 5 mm in
length, and 1.5 to 2 mm in internal diameter) were pre-
pared from a single artery. Some of the rings were used
immediately for pharmacological studies, whereas others
were snap-frozen and stored in liquid nitrogen for sub-
sequent protein extraction.
Endothelial function was evaluated by the cumulative
acetylcholine (Ach) dose response curve for pulmonaryartery rings isolated from smokers or never-smokers.
Under our experimental conditions, endothelial dysfunc-
tion was defined as an impaired response to Ach (such
as a lack of relaxation, or even contraction).
The pharmacological experiments
Arterial rings were mounted in bath organs, as previously
described [5]. Briefly, rings were suspended on tissue
hooks in 5 ml organ baths containing Krebs-Henseleit so-
lution at 37°C and bubbled with 95% O2 and 5% CO2.
Each preparation was connected to a force displacement
transducer (Statham UF-1) and changes in isometric ten-
sion were recorded. An initial tension of 1 g was applied
to the rings, which were then left to equilibrate for 30 mi-
nutes (with regular changes in fresh Krebs-Henseleit solu-
tion) until a stable resting tension (RT1) was obtained.
The rings’ responsiveness was confirmed by adding KCl
(to 40 mM), which induced contraction. Viable rings were
then washed until full relaxation had occurred (resting
tension 2, RT2), and were left to rest for 20 minutes. The
rings were then precontracted with L-phenylephrine (PE)
dichloride (10−5 M) to obtain a stable plateau of contrac-
tion. Serial dilutions of Ach chloride were then added, in
order to establish a cumulative dose response curve (10−10
to 10−4 M). Relaxation in response to Ach was expressed
as a percentage of the contraction induced by PE. A con-
tractile response to Ach was expressed as a negative value.
Endothelium-independent relaxation was assessed by
measuring the response to sodium nitroprusside 10−5 M
at the end of each experiment.
For each patient, some rings were pre-treated with vari-
ous drugs for 30 minutes after PE precontraction. To test
the hypothesis whereby NOS lacked substrate, we supple-
mented the rings with L-arg (10−3 M). To evaluate the role
of arginases in pulmonary vasoactivity, we assessed the
effects of the arginase antagonist N(omega)-hydroxy-
nor-l-arginine (NorNOHA; 10−5 M). Lastly, we tested
the effect of the NO potentiator genistein (10−6 M). The
concentrations of these drugs producing 50% of the
maximum effect were determined in preliminary experi-
ments (data not shown).
All drugs were purchased from Sigma (St. Louis, MO),
with the exception of Ach (provided by Pharmacie Centrale
des Hôpitaux, Paris, France).
All experiments were performed in duplicate. The inter-
ring variability was always below 10%.
Western blot analyses
Nitric oxide synthase 3 and arginases 1 and 2 were
assayed in homogenized extracts of pulmonary arteries,
as previously described [5]. Total proteins were extracted
with a lysis buffer (10 mM Tris–HCl pH 7.4, 50 mM
NaCl, 0.1% NP-40, and 20% antiprotease cocktail) and
were measured with a bicinchoninic acid protein assay kit
Table 1 Clinical characteristics of the study population
Characteristics Smokers Never-smokers p
(n = 29) (n = 10)
Age, years (median, range) 63 (44–78) 55 (49–73) 0.11
Male:female ratio 23:6 7:3 0.16
Tobacco, pack-years (mean, range) 48 (10–120) NA
Current smokers (n=) 15 NA
FEV1, % predicted (mean, range) 88 (66–118) 92 (82–103) 0.33
OLD (n=) 2 0 1
NA: not appliable; FEV1: forced expiratory volume in 1 second; OLD: presence
of an obstructive pulmonary disease, defined as post-bronchodilator FEV1/forced
vital capacity < 70%.
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instructions. Total proteins (30 μg/lane) were separated
by electrophoresis on a 10% sodium dodecyl sulphate–
polyacrylamide gel, transferred onto nitrocellulose mem-
branes and immunodetected. Nonspecific binding was
blocked by incubation with 10% milk powder in Tris-
buffered saline for 1 h at room temperature. The blots
were incubated with a rabbit polyclonal antibody against
NOS3 (sc-654, 1:150 dilution, Santa Cruz Biotechnology,
Inc., Dallas, TX) or goat polyclonal antibodies against argi-
nases I or II (sc-18351 and sc 18360, 1:200 dilution, Santa
Cruz Biotechnology) followed by biotinylated secondary
antibodies: anti-rabbit IgG peroxidase conjugate (sc-2004,
1:1,000 dilution; Santa Cruz Biotechnology) or anti-goat
IgG peroxidase conjugate (sc-2922, 1:1,000 dilution; Santa
Cruz Biotechnology). Membranes were subsequently
stripped and reprobed with a mouse monoclonal antibody
against β-actin (AANO2; dilution: 1:1,000; Cytoskeleton,
Inc., Denver, CO). The proteins were detected with an
enhanced chemiluminescence (ECL) kit and high-
performance chemiluminescence film (GE Healthcare,
Aulnay sous Bois, France). The intensities of protein
staining on the immunoreactive Western blot bands
were analyzed with ImageJ image analysis software. The
relative amounts of immunoreactive proteins were cal-
culated by dividing the scanning unit value by the re-
spective value of β-actin protein (probed with the
primary anti-β-actin antibody) and expressed in arbi-
trary units.Statistical analysis
Results are expressed as the mean ± standard error of
the mean (SEM), except where otherwise specified. Data
were analysed with NCSS9 (NCSS, LLC. Kaysville, UT)
and GraphPad Prism version 5.00 for Windows (GraphPad
Software, San Diego, CA) For intergroup comparisons,
a non-parametric analysis of variance (ANOVA) was
followed by Dunn’s test for multiple comparisons. For
comparisons of condition (i.e. Ach dose–response curves
in the presence and absence of another drug), a repeated
measures ANOVA was followed by a Tukey-Kramer test
for multiple comparisons. Fischer’s exact test or Mann–
Whitney test was used for categorical variables. A p
value <0.05 was considered to be statistically significant.Results
Subjects
Explants were obtained from 29 current smokers/
ex-smokers and 10 never-smokers. Smoking history was
the only demographic or clinical factor that differed sig-
nificantly when comparing smokers and never-smokers
(Table 1).Tobacco smoking impairs the relaxant response of the
pulmonary artery
The vasodilatory response to Ach was strongly altered in
smokers, when compared with never-smokers (10 ± 7%
vs. 42 ± 8% at 10−4 M Ach, respectively, p < 0.01, Figure 1,
panel A). Closer analysis of responses of the rings from
the smokers enabled us to distinguish between two sub-
groups: 11 patients exhibited endothelial dysfunction as
defined above (the ED+ subgroup), whereas the remaining
18 exhibited a relaxant response (forming the ED− sub-
group) similar to that seen in never-smokers (−23 ± 10%
vs. 31 ± 4% and 42 ± 8% at 10−4 M Ach in the ED+ sub-
group, the ED− subgroup and never-smokers, respectively;
p < 0.01, Figure 1, panel B). The ED+ vs. ED− subgroups
did not differ significantly in terms of baseline tensions or
peak vasoconstriction in response to PE (RT1: 0.9 ± 0.1 g
vs. 0.9 ± 0.1 g (ns), respectively; RT2: 0.8 ± 0.1 g vs. 0.9 ±
0.1 g (ns), respectively; PE-induced tension: 1.2 ± 0.2 g vs.
1.4 ± 0.1 g, respectively; data not shown). SNP 10−5 M in-
duced a relaxant response in all patients, including those
with an endothelial dysfunction, discarding the fact that
the lack of endothelium-dependant response could be due
to the damage of the pulmonary artery during its manipu-
lation (data not shown). In neither subgroup was the re-
sponse to Ach correlated with age, gender, cumulative
tobacco smoking, COPD, forced expiratory flow in 1 second
(FEV1), systolic pulmonary artery pressure (as measured by
echocardiography, when available) or other possible con-
founders of endothelial dysfunction, such as hypertension,
hypercholesterolemia, ongoing treatment with statins or
vasodilators, diabetes mellitus, and prior treatment with
cytotoxic drugs (Table 2).
All of the 11 ED+ patients had undergone pre-operative
echocardiography and none had displayed an elevated sys-
tolic pulmonary artery pressure at rest.
L-arginine supplementation improves
endothelium-dependent function
To investigate whether endothelial dysfunction could be
explained by a lack of the NOS substrate L-arg, we
AB
Figure 1 Pulmonary endothelial function, represented as cumulative Ach dose response curves in pulmonary artery rings from
smokers (n = 29) and never-smokers (n = 10). Smokers had impaired relaxation in response to Ach, when compared with never-smokers
(p < 0.01; panel A). The smokers were divided into two subgroups according to the presence (ED+, n = 11) or absence (ED−, n = 18) of pulmonary
endothelial dysfunction (p < 0.01; panel B).
Table 2 Clinical characteristics of patients according to
the presence or absence of endothelial dysfunction
Characteristics Smokers p
ED+ (n = 11) ED− (n = 18)
Age, years (median, range) 63 (44–77) 62 (48–78) 0.86
Male:Female ratio 7:4 16:2 0.11
Tobacco, pack-years (mean, range) 54 (30–120) 46 (10–90) 0.74
Current smokers (n=) 5 10 0.96
FEV1, % predicted (mean, range) 79 (67–101) 92 (66–118) 0.06
OLD (n=) 0 2 0.51
GOLD 1 (n=) 0 1 1
GOLD 2 (n=) 0 1 1
Prior chemotherapy (n=) 2 4 1
Hypercholesterolemia (n=) 2 1 0.53
Hypertension (n=) 2 5 0.68
Diabetes mellitus (n=) 1 3 1
Treatment by statin (n=) 1 5 0.36
Vasodilating treatment (n=) 1 3 1
ED+: endothelial dysfunction; ED−: no endothelial dysfunction; FEV1: forced
expiratory volume in 1 second; OLD: presence of an obstructive pulmonary
disease, defined as post-bronchodilator FEV1/forced vital capacity < 70%.
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in the presence and absence of substrate supplementation
(n = 6). Supplementation with L-arg (10−3 M) significantly
improved endothelial function but did not restore a
normal vasodilatory response (−4 ± 10% vs. -32 ± 10%
at 10−4 M Ach in the presence and absence of L-arg,
respectively; p = 0.006; Figure 2).
Arginase inhibition restores endothelium-dependent dilation
We tested the effect of the arginase inhibitor NorNOHA
(10−5 M) on the ED+ samples’ response to Ach (n = 4).Figure 2 Effect of L-arg (10−3 M) supplementation on endothelial
function. L-arg supplementation improved endothelial function in ED+
samples (n = 6; p = 0.006).
Figure 4 Effect of genistein (10−6 M) on endothelial function.
Genistein did not improve endothelial function in ED+ patients (n = 4).
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function and restored the relaxant response to Ach (18
± 9% vs. -1 ± 9% at 10−4 M Ach in the presence and ab-
sence of NorNOHA, respectively; p = 0.0002; Figure 3).
Effect of genistein on endothelial dysfunction
The phytoestrogen genistein can potentially enhance
NO production by activating NOS3. We sought to deter-
mine whether the compound could improve the vasodila-
tory response in ED+ subjects (n = 4). Genistein (10−6 M)
did not improve this response (−13 ± 7% vs. -14 ± 3% at
10−4 M Ach in the presence and absence of genistein,
respectively, NS) (Figure 4).
NOS and arginase expression
In pulmonary artery samples analysed with Western
blotting, arginase I protein expression was significantly
higher in ED+ patients (n = 3) than in ED− patients (n = 4)
(mean relative expression: 2.45 ± 0.15 vs. 1.19 ± 0.25, re-
spectively; p < 0.05; Figure 5, panel A). In contrast, levels
of arginase II expression were similar the ED+ (n = 4) and
ED− subgroups (n = 4) (Figure 5, panel B). Likewise, the
ED+ and ED− subgroups did not differ significantly in
terms of the expression of NOS3 in pulmonary artery
rings (mean relative expression: 1.34 ± 0.2 vs. 1.76 ± 1.2,
respectively, NS) (Figure 6).
Discussion
We found that the impairment in pulmonary vasodila-
tion observed in a significant proportion of smokers may
be explained by increased arginase I protein expression
in the pulmonary artery. L-arg supplementation reduced
the endothelial dysfunction, and arginase inhibition re-
stored a normal vasodilatory, endothelium-dependent
response in ED+ patients. Lastly, we confirmed our pre-
vious report of the high prevalence of pulmonary endo-
thelial dysfunction in smokers (38% in the present
study) [5], even in those with normal lung function. In-
deed, our smokers and nonsmokers were quite similar in
terms of clinical characteristics (and cardiovascular riskFigure 3 Effect of arginase inhibition by NorNOHA (10−5 M) on
endothelial function. NorNOHA improved endothelial function in
ED+ samples (n = 4) by restoring a vasodilatory response to
Ach (p = 0.0002).factors in particular), and there were only two smokers
in the study population with overt, moderate COPD,
Global Initiative for Obstructive Lung Disease (GOLD)
stage 2. The other smokers had normal lung function.
Taken as a whole, our present data strengthen the gen-
eral hypothesis whereby tobacco smoking has a direct,
harmful influence on the pulmonary vasculature.
In terms of putative mechanisms, our study focused
on the NO pathway because changes in NO bioavailabil-
ity are thought to have a major role in endothelial dys-
function [6]. Nitric oxide acts as an endothelial central
signalling molecule [24] that controls vascular tone and
structure by decreasing vascular smooth muscle cell pro-
liferation [25,26]. A decreased NO bioavailability, as we
hypothesize in smokers exhibiting an abnormal vasore-
laxation (ED+ subjects) might partly result from a limita-
tion in substrate [6,21,15]. Indeed, arginase and NOS
compete for their common substrate, L-arginine, and an
overactive arginase might limit substrate availability for
NOS and therefore NO production. In addition, an in-
creased oxidative stress might also partly account for the
vascular dysfunction showed in this study. Our experi-
ments revealed that NO bioavailability was impaired in
ED+ subjects as a result of absolute and relative substrate
deficiencies. Indeed, the arginase inhibitor NorNOHA was
able to partly restore a relaxant response, suggesting that
ED+ subjects have elevated arginase activity. This can be
explained by the elevated vascular arginase I protein ex-
pression observed in ED+ samples. Taken as a whole, these
results suggest that NO production by NOS3 is limited by
competition with arginase I for the common substrate
L-arg, which ultimately leads to a relative substrate defi-
ciency. Enhanced arginase activity has been associated
with the systemic endothelial dysfunction observed in
various conditions. Some cell-based and preclinical studies
using arginase inhibitors have provided convincing evi-
dence for arginase’s harmful effects in cardiovascular dis-
eases [15,18] in which arginase expression is upregulated
[17,27]. Although data for the pulmonary circulation are
scarce, harmful effects of arginase upregulation and/or of
low L-arg levels have also been demonstrated in models of
ED+ED
ED+ ED
ED-
-
Arginase I
Actine
Arginase II
Actine
A
B
Figure 5 Protein expression of arginases I and II in pulmonary artery samples from ED+ and ED− patients. Arginase I protein expression
(as analysed by Western blotting) was higher in ED+ patients (n = 3) than in ED- patients (n = 4), p<0.05; panel A. Arginase II protein expression
was similar in ED+ (n = 4) and ED− patients (n = 4); panel B. The vertical line indicates that the gel was cut.
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knowledge, our study is the first to have demonstrated the
role of increased arginase activity in tobacco associated-
pulmonary endothelial dysfunction. Increased arginase
activity has also been associated with airway hyperre-
sponsiveness [33,34]; we previously demonstrated that
increased arginase activity is involved in airway sensitiv-
ity in smokers [35]. Overall, elevated arginase activity
may be one of the mechanisms underlying both pulmon-
ary arterial dysfunction and bronchial dysfunction [36].
Studies with L-arg supplementation have shown in-
consistent effects on both systemic and pulmonary
endothelial functions [37-39]. In the present study, L-argFigure 6 Expression of NOS3 in pulmonary artery samples from ED+ a
and ED− (n = 4) patients.supplementation reduced the dysfunction in ED+ patients
but did not restore a normal vasodilatory response; this
finding suggests an absolute lack of substrate in these indi-
viduals. The lack of complete restoration of a normal
vasodilatory response might involve (amongst others) add-
itional mediators of pulmonary tobacco associated- endo-
thelial dysfunction, such as increased activation of the
endothelin (ET)-1/ET-A pathway (as we have previously
reported [5]). In line with the recent literature, the ED+
and ED− subgroups did not differ significantly in terms
of expression of NOS3 (the arginases’ competitor for
NO production) in the pulmonary vasculature [40]. The
exact relationship between cigarette smoke and NOS3ED+ ED-
NOS 3
Actin
nd ED− patients. NOS3 protein expression was similar in ED+ (n = 4)
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studies, smoke exposure has variously led to a decrease
or an increase in NOS3 expression [41-43]. Given that
NOS3 is tightly regulated by post-translational lipid
modifications, protein-protein interactions and protein
phosphorylation [44], its protein expression levels are
not correlated with its activity. The fact that genistein
(a strong potentiator of NO production via NOS3 acti-
vation) did not enhance vasorelaxation in ED+ subjects
suggests that impaired NOS3 activity does not have a
role in endothelial dysfunction in that context.
Conclusions
Arginase I overexpression and activity may be involved
in tobacco-induced pulmonary endothelial dysfunction.
The present results are of interest because they suggest
that increased arginase activity may be one of the mech-
anisms underlying both pulmonary arterial dysfunction
and bronchial dysfunction. Further research must explore
the effects of combined L-arg supplementation and argi-
nase inhibition and assess the potential value of these
approaches in resolving endothelial dysfunction in the
setting of tobacco exposure.
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